VEGFA and non-small cell lung carcinoma: The most common antiangiogenics applied in the clinic for advanced NSCLC patients include: the monoclonal antibodies of VEGF, such as bevacizumab and ramucirumab; small molecule vascular endothelial growth factor receptor 2 (VEGFR-2); and the TKI apatinib and small molecule multitarget TKIs, such as anlotinib.